About MacuLogix

MacuLogix is a pioneer in the early detection and tracking of age-related macular degeneration (AMD). MacuLogix’ AdaptDx™ has received FDA 510(k) clearance for measurement of dark adaptation function and patient testing has been completed to support validation as a diagnostic for AMD. However, the AdaptDx™ is not currently cleared for sale as a diagnostic. In addition, the AdaptDx™ is being used by a number of pharmaceutical companies in the development of drugs for early AMD.

website icon
Website
employees icon
Employees
industry icon
Industry
IT Services and IT Consulting
location icon
Phone number
717-583-1220
location icon
Headquarter
Hummelstown, Pennsylvania
description icon
Founded
2004

MacuLogix Alternatives

Industry
Therapeutics
Industry
Therapeutics
Industry
Therapeutics
Industry
Therapeutics

Frequently Asked Questions about MacuLogix

Who are the decision makers in MacuLogix?

The decision makers in MacuLogix are Dave Miller, Harold Mapes, Will Urey, etc. Click to Find MacuLogix decision makers emails.

Supercharge your
Prospecting &
Outreach with
ContactOut

Search Portal

Find countless prospects outside of LinkedIn fast

Accelerate prospecting with instant access to 350M professionals from 40M companies with the right contact details.

Discover the source of our data

Learn more